Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Men Undergoing Androgen Deprivation Therapy
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
OUTLINE:
Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98109
- Fred Hutch/University of Washington
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Signed informed consent
- Histologically confirmed adenocarcinoma of the prostate
- Non-castrate disease with a serum testosterone level >= 50 ng/dL (1.73 nmol/L) at baseline
- No evidence of distant metastatic disease on baseline computed tomography-chest, abdomen and pelvis (CT-CAP) and bone scans
Patients will be stratified by the presence or absence of pre-existing cardiovascular disease defined as at least one of the following:
- Prior myocardial infarction >= 30 days before enrollment
Prior revascularization procedure >= 30 days before consent, including:
- Coronary artery stent placement or balloon angioplasty
- Coronary artery bypass graft surgery
- Stent placement or balloon angioplasty to a carotid, iliac, femoral, or popliteal artery
- Carotid endarterectomy surgery
- Vascular bypass surgery of the iliac, femoral, or popliteal artery
- Results from angiogram or CT angiogram of coronary, carotic, iliac, femoral, or popliteal arteries that documents at least one vascular stenosis >= 50% at any time point before enrollment
- Carotid ultrasound results that shows stenosis >= 50% at any time point before enrollment
- Ankle-brachial pressure index < 0.9 at any time point before enrollment
- Intent to initiate continuous androgen deprivation therapy (ADT) for at least 12 months
Exclusion Criteria:
- No prior treatment with ADT at time of study entry. (Prior neoadjuvant/adjuvant ADT is allowed only if the last injection of a depot formulation wore off at least 12 months prior to enrollment)
- Previous or concurrent hormonal or systemic therapy for prostate cancer including: anti-androgens, estrogens, megestrol acetate, ketoconazole, abiraterone, enzalutamide, or chemotherapy. (Prior or planned neoadjuvant bicalutamide for prevention of tumor flare is allowed)
- Plans to start or continue treatment with an investigational product after enrollment
- Poorly controlled type 1 or type 2 diabetes mellitus, based on hemoglobin A1c, as judged by the investigator
- Prior or planned surgical castration
- Poorly controlled hypertension at time of study entry, as judged by the investigator
- Myocardial infarction or stroke < 30 days prior to enrollment
- Coronary, carotid, or peripheral artery revascularization < 30 days prior to enrollment
- Planned or scheduled cardiac surgery or percutaneous coronary intervention (PCI) procedure that is known at the time of enrollment
- Mental incapacity or language barrier precluding adequate understanding or cooperation
- Inability to tolerate magnetic resonance imaging (MRI) imaging, or both Lupron and Degarelix
- Any other clinically significant disorder which may affect the subject's health or the outcome of the trial as judged by the investigator
- Estimated glomerular filtration rate (eGFR) < 45
- History of allergy to gadolinium contrast agent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Clinical Evaluations
Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
|
Hjælpestudier
Undergo clinical evaluations
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in visual characterization of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results after Andorgen Deprivation Therapy
Tidsramme: 12 Months
|
Change From Baseline visual characterization scan results at 12 months
|
12 Months
|
|
Change standardized uptake values of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results
Tidsramme: 12 Months
|
Change from baseline standardized uptake values in select regions of interest at 12 months
|
12 Months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cognitive test results: Story recall
Tidsramme: 12 months
|
Change in baseline Story Recall results at 12 months
|
12 months
|
|
Cognitive Test Results: Change in Montreal Cognitive Assessment (MOCA)
Tidsramme: 12 Months
|
Change in baseline MOCA score results at 12 months
|
12 Months
|
|
Cognitive Test Results: Change in Clinical Dementia Rating Scale
Tidsramme: 12 Months
|
Change in baseline Clinical Dementia Rating Scale score at 12 months
|
12 Months
|
|
Cognitive Test Results: Digit span
Tidsramme: 12 Months
|
Change in baseline Digit span results at 12 months
|
12 Months
|
|
Cognitive Test Results: Letter number sequencing
Tidsramme: 12 Months
|
Change in baseline Letter number sequencing results at 12 months
|
12 Months
|
|
Cognitive Test Results: Stroop Test Results
Tidsramme: 12 Months
|
Change in baseline Stroop Test Results at 12 months
|
12 Months
|
|
Cognitive Test Results: Symbol Digit Modalities Test
Tidsramme: 12 Months
|
Change in baseline Symbol Digit Modalities Test score at 12 months
|
12 Months
|
|
Cognitive Test Results: Visuo-Spatial Learning Test
Tidsramme: 12 Months
|
Change in baseline Visuo-Spatial Learning Test results at 12 months
|
12 Months
|
|
Cognitive Test Results: Rey auditory verbal learning test (RVLT)
Tidsramme: 12 Months
|
Change in baseline Rey auditory verbal learning test (RVLT) score at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in CRP
Tidsramme: 12 Months
|
Change in baseline CRP values at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGFBP3
Tidsramme: 12 Months
|
Change in baseline IGFBP3 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGFBP1
Tidsramme: 12 Months
|
Change in baseline IGFBP1 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGF-1
Tidsramme: 12 Months
|
Change in baseline IGF-1 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IL-6
Tidsramme: 12 Months
|
Change in baseline IL-6 at 12 months
|
12 Months
|
|
Metabolic Markers: Change in HgbA1C
Tidsramme: 12 Months
|
Change in baseline HgbA1C at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Estradiol
Tidsramme: 12 Months
|
Change in baseline Estradiol at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Follicle Stimulating Hormone (FSH)
Tidsramme: 12 Months
|
Change in baseline Change in Follicle Stimulating Hormone (FSH) at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Leptin
Tidsramme: 12 Months
|
Change in baseline Leptin at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Adiponectin
Tidsramme: 12 Months
|
Change in baseline Adiponectin at 12 months
|
12 Months
|
|
Metabolic Markers: Change in homeostatic model assessment of insulin resistance (HOMA-IR)
Tidsramme: 12 Months
|
Change in baseline HOMA-IR values at 12 months; Calculated based on fasting glucose and insulin test results.
|
12 Months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Evan Yu, Fred Hutch/University of Washington Cancer Consortium
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- RG1001903
- 9939 (FHCRC)
- NCI-2018-01618 (Registry Identifier: CTRP)
- 5P30CA015704 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .